BioPharma Dive January 21, 2025
Ben Fidler

Sionna aims to challenge Vertex in cystic fibrosis, while Odyssey is developing targeted medicines for autoimmune conditions.

Dive Brief:

  • Two biotechnology startups on Friday revealed plans to launch initial public offerings, extending a step-up in IPO activity among privately held drug companies.
  • Sionna Therapeutics is working on therapies for cystic fibrosis, several of which are in early-stage testing. Odyssey Therapeutics aims to tap Wall Street to develop targeted drugs for immune diseases, the most advanced of which could begin a Phase 2 trial in ulcerative colitis this quarter.
  • Sionna and Odyssey are the fourth and fifth biotech companies to file for IPOs since late December. Over the last three years, however, bursts of IPO activity have typically been followed...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
Google DeepMind CEO: AI-Designed Drugs Coming to Clinical Trials in 2025
Moderna gets $590M from US government for bird flu vaccine
Why costly gene therapy is top of mind for benefits administrators
CEPI provides $6.2m to push first mRNA-based Rift Valley fever vaccine into trial

Share This Article